Get the Stockscreener App
73.17
0.18%
-0.13
After Hours:
73.17
Intra Cellular Therapies Inc stock is traded at $73.17, with a volume of 354.34K.
It is down -0.18% in the last 24 hours and down -0.15% over the past month.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
See More
Previous Close:
$73.30
Open:
$73
24h Volume:
354.34K
Relative Volume:
0.42
Market Cap:
$7.71B
Revenue:
$563.44M
Net Income/Loss:
$-84.30M
P/E Ratio:
-45.45
EPS:
-1.61
Net Cash Flow:
$-61.23M
1W Performance:
-3.48%
1M Performance:
-0.15%
6M Performance:
+5.74%
1Y Performance:
+40.47%
1-Day Range:
$72.78
$73.91
1-Week Range:
$72.54
$76.22
52-Week Range:
$45.50
$84.89
Intra Cellular Therapies Inc Stock (ITCI) Company Profile
Name
Intra Cellular Therapies Inc
Sector
Phone
212-923-3344
Address
430 EAST 29TH STREET, NEW YORK, NY
Intra Cellular Therapies Inc Stock (ITCI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Dec-11-23 | Initiated | TD Cowen | Outperform |
| Apr-20-23 | Initiated | Morgan Stanley | Overweight |
| Aug-22-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Jun-14-22 | Initiated | UBS | Buy |
| Apr-22-22 | Initiated | Piper Sandler | Neutral |
| Feb-16-22 | Initiated | Goldman | Buy |
| Sep-23-21 | Initiated | Needham | Buy |
| Dec-15-20 | Initiated | BofA Securities | Buy |
| Dec-10-20 | Initiated | Goldman | Buy |
| Feb-20-20 | Initiated | Evercore ISI | Outperform |
| Jan-31-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-24-19 | Reiterated | Canaccord Genuity | Buy |
| Aug-12-19 | Initiated | Jefferies | Buy |
| Feb-26-18 | Initiated | JP Morgan | Overweight |
| Feb-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Dec-15-17 | Initiated | Canaccord Genuity | Buy |
| Nov-08-17 | Upgrade | SunTrust | Hold → Buy |
| Sep-07-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-30-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Aug-24-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Aug-23-17 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| May-02-17 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| May-02-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| May-01-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-29-16 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-29-16 | Downgrade | SunTrust | Buy → Neutral |
View All
Intra Cellular Therapies Inc Stock (ITCI) Latest News
Intra-Cellular Therapies' SWOT analysis: caplyta drives growth as mdd potential lifts stock - Investing.com India
Algert Global LLC Trims Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Hsbc Holdings PLC Reduces Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
D. E. Shaw & Co. Inc. Acquires 190,080 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Scientech Research LLC Invests $2.42 Million in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
499,015 Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Purchased by Marshall Wace LLP - MarketBeat
Point72 Europe London LLP Takes $2.21 Million Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Neurological diseases index falls; Sarepta and Intra-Cellular report gains - BioWorld Online
The Attractiveness of Investing In Intra-Cellular Therapies Inc (ITCI) is Growing - Knox Daily
20,385 Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Acquired by Point72 DIFC Ltd - MarketBeat
US FDA approves IntraBio's drug for rare genetic disease - Yahoo! Voices
Intact Financial (TSE:IFC) Sets New 12-Month High at $23.76 - Defense World
Weekly Investment Analysts’ Ratings Changes for Incyte (INCY) - Defense World
Integral Acquisition Co. 1 (NASDAQ:INTE) Shares Acquired by Berkley W R Corp - Defense World
We Think Inter Parfums (NASDAQ:IPAR) Can Stay On Top Of Its Debt - Simply Wall St
Itau Unibanco Holding S.A. ADR [ITUB] moved up 0.44: Why It’s Important - The DBT News
Intapp stock soars to 52-week high, touches $50 mark - Investing.com India
Investcorp Credit Management BDC (ICMB) to Release Earnings on Wednesday - Defense World
Pacer Advisors Inc. Sells 1,059 Shares of Intercontinental Exchange, Inc. (NYSE:ICE) - Defense World
Glazer Capital LLC Sells 3,439 Shares of Integral Acquisition Co. 1 (NASDAQ:INTE) - Defense World
Skandinaviska Enskilda Banken AB publ Increases Position in Itron, Inc. (NASDAQ:ITRI) - Defense World
Long Term Trading Analysis for (ICG) - Stock Traders Daily
Intech Investment Management LLC Boosts Stake in Intercontinental Exchange, Inc. (NYSE:ICE) - Defense World
BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Acquires 25,714 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) - MarketBeat
Recent Insider Activity Could Benefit Intercontinental Exchange Inc (ICE) - Knox Daily
Intapp, Inc. (NASDAQ:INTA) Shares Sold by Hood River Capital Management LLC - MarketBeat
Lombard Odier Asset Management Europe Ltd Invests $4.11 Million in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Has $87.23 Million Holdings in Intuit Inc. (NASDAQ:INTU) - MarketBeat
Inter Parfums, Inc. (NASDAQ:IPAR) Stake Boosted by Envestnet Asset Management Inc. - MarketBeat
IAC Inc. (NASDAQ:IAC) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Itim Group PLC Announces Strong Mid-Year Financials - TipRanks
Insider Selling: InterDigital, Inc. (NASDAQ:IDCC) Director Sells 2,500 Shares of Stock - Defense World
Donald F. Coleman Sells 58,003 Shares of Intapp, Inc. (NASDAQ:INTA) Stock - Defense World
Discovery Capital Management LLC CT Invests $2.45 Million in Intel Co. (NASDAQ:INTC) - Defense World
InterDigital director sells $346,800 in company stock By Investing.com - Investing.com Canada
Intapp chief product officer unloads over $4.9 million in company stock - Investing.com UK
Intapp COO sells over $4.4 million in company stock By Investing.com - Investing.com UK
Cyrus J. Lawrence LLC Has $9 Million Stake in Intuit Inc. (NASDAQ:INTU) - Defense World
3,557 Shares in Intercontinental Exchange, Inc. (NYSE:ICE) Bought by Itau Unibanco Holding S.A. - Defense World
Tairen Capital Ltd Buys Shares of 6,000 Intuit Inc. (NASDAQ:INTU) - Defense World
Intercontinental Exchange, Inc. (NYSE:ICE) Shares Sold by Interval Partners LP - Defense World
Integral Health Asset Management LLC Has $9.93 Million Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Defense World
Innodata Target of Unusually Large Options Trading (NASDAQ:INOD) - Defense World
IAC Inc. (NASDAQ:IAC) Position Lessened by Applied Fundamental Research LLC - Defense World
Intra-Cellular announces presentations at 2024 ECNP Congress - TipRanks
Interface (NASDAQ:TILE) Reaches New 52-Week High at $19.45 - MarketBeat
Pacer Advisors Inc. Acquires 4,730 Shares of Intuit Inc. (NASDAQ:INTU) - Defense World
Intapp (NASDAQ:INTA) Price Target Raised to $60.00 at Stifel Nicolaus - MarketBeat
Intra-Cellular Therapies Announces Presentations at the - GlobeNewswire
Intra-Cellular Therapies Announces Presentations at the 2024 European College of ... - The Bakersfield Californian
Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress - GlobeNewswire Inc.
Intra Cellular Therapies Inc Stock (ITCI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.23%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):